Breaking Down SG&A Expenses: Protagonist Therapeutics, Inc. vs Novavax, Inc.

A Tale of Two Biotechs: SG&A Expenses Over Time

In the competitive world of biotechnology, managing expenses is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Protagonist Therapeutics, Inc. and Novavax, Inc. from 2014 to 2023. Over this period, Novavax's SG&A expenses surged by over 2,200%, peaking in 2022, reflecting its aggressive expansion and marketing strategies. In contrast, Protagonist Therapeutics saw a more modest increase of around 1,700%, indicating a steady growth trajectory. Notably, Novavax's expenses in 2023 were approximately 14 times higher than those of Protagonist Therapeutics, highlighting the scale of its operations. This financial snapshot underscores the differing strategic approaches of these two companies in navigating the biotech landscape. As the industry evolves, understanding these financial dynamics offers valuable insights into the operational priorities and market positioning of leading biotech firms.